0001493152-24-007456.txt : 20240221 0001493152-24-007456.hdr.sgml : 20240221 20240221193058 ACCESSION NUMBER: 0001493152-24-007456 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240220 FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SAHAREK JOHN P. CENTRAL INDEX KEY: 0001632091 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35814 FILM NUMBER: 24661791 MAIL ADDRESS: STREET 1: 12264 EL CAMINO REAL STREET 2: SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER NAME: FORMER CONFORMED NAME: Saharek John DATE OF NAME CHANGE: 20150128 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HARROW, INC. CENTRAL INDEX KEY: 0001360214 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 450567010 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 102 WOODMONT BLVD STREET 2: SUITE 610 CITY: NASHVILLE STATE: TN ZIP: 37215 BUSINESS PHONE: 615.733.4731 MAIL ADDRESS: STREET 1: 102 WOODMONT BLVD STREET 2: SUITE 610 CITY: NASHVILLE STATE: TN ZIP: 37215 FORMER COMPANY: FORMER CONFORMED NAME: HARROW HEALTH, INC. DATE OF NAME CHANGE: 20181228 FORMER COMPANY: FORMER CONFORMED NAME: Imprimis Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20120301 FORMER COMPANY: FORMER CONFORMED NAME: TRANSDEL PHARMACEUTICALS INC DATE OF NAME CHANGE: 20070912 4 1 ownership.xml X0508 4 2024-02-20 0 0001360214 HARROW, INC. HROW 0001632091 SAHAREK JOHN P. C/O HARROW HEALTH, INC. 102 WOODMONT BLVD, SUITE 610 NASHVILLE TN 37205 0 1 0 0 CEO of ImprimisRx 0 Common stock 2024-02-20 4 M 0 30000 10.67 A 262419 D Common stock 2024-02-20 4 M 0 12616 10.67 D 249803 D RSU 0.00 2024-02-20 4 M 0 30000 0 D Common Stock 30000 0 D The listed acquired 30,000 shares of Harrow, Inc. ("Harrow")_common stock represent restricted stock units (RSUs") granted to Mr. Saharek on February 19, 2021 under the Issuer's 2017 Stock Incentive and Awards Plan, as amended. The RSUs vested after a three-year period following the award date. 12,616 shares of Harrow common stock listed as disposed were withheld from issuance by Harrow to satisfy Mr. Saharek's payroll tax liability incident related to the vesting of the RSUs. Such withholding did not involve any market sales or other market transactions. /s/ John P. Saharek 2024-02-21